Trial · NCT04046887
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
NCT04046887, Phase 1, Terminated, Patrick Joseph Loehrer Sr.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC). Trials, record NCT04046887. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04046887
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
- NCT number
- NCT04046887
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 14 participants, actual
- Lead sponsor
- Patrick Joseph Loehrer Sr.
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- Lonsurf, Gemcitabine, Nab-Paclitaxel
- First posted
- 2019-08-06
- Last updated
- 2024-01-05
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency of Dose Limiting Toxicities (DLTs) | 28 days (Cycle 1) | Number of DLTs observed |
| Secondary | Frequency of adverse events in the safety evaluable population | from start of treatment until 30 days after treatment discontinuation (i.e up to 2 years) | safety and toxicity data will be assessed using NCI CTCAE v5.0 |
| Secondary | Response rate to the combination of lonsurf, gemcitabine, and nab-paclitaxel in the efficacy evaluable population | from start of treatment until treatment discontinuation (i.e. up to 2 years) | Using RECIST 1.1 |
| Secondary | Median Overall Survival (mOS) of the treated population | from start of treatment until death or last known follow up (i.e up to 2 years) | |
| Secondary | Median Progression-free Survival (mPFS) of the treated population | from start of treatment until disease progression or last follow up (i.e. up to 2 years) | |
| Secondary | Disease control rate (DCR) | 8 weeks | Disease control rate (DCR) as defined by (complete response + partial response + stable disease) |
| Secondary | European Organization for Research and Treatment of Cancer quality of life questionnaire | Day 1 of each cycle(each cycle is 28 days),from start of treatment until disease progression or discontinuation of treatment (i.e. up to 2 years) | Scale scores were calculated by averaging items within scales and transforming average scores linearly. All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04046887
GET https://conductscience.org/api/trials/v1/NCT04046887/registered